Navigation Links
Harvest Technologies Announces Patient Education Website, www.CLIclinicalstudy.com : Supports first randomized, placebo-controlled clinical trial in the U.S. using autologous adult stem cells to treat patients with end-stage Critical Limb Ischemia
Date:10/28/2008

Harvest Technologies Corp. (www.harvesttech.com) announced today that its new patient-education website, www.CLIclinicalstudy.com, is now “live”. The site is intended to offer persons who are considering enrolling in the Company’s clinical trial and their referring physicians important information related to the study’s design, the science that underlies it, and the location of the study’s sites.

PLYMOUTH, Mass. (Business Wire EON) October 28, 2008 -- The Food and Drug Administration (FDA) has granted Investigational Device Exemption (IDE) approval to Harvest Technologies to conduct a randomized, controlled, double-blind, multicenter clinical trial using the Company's BMAC System to prepare a composition of bone marrow stem cells to treat patients with Critical Limb Ischemia (CLI). This "feasibility trial" will enroll a total of 48 subjects. Subjects who enroll in this study have exhausted all surgical and procedural options and are at extreme risk for major amputation. The BMAC System is a point-of-care device for concentrating a patient's own (autologous) bone marrow stem cells in approximately 15 minutes at the bedside. The clinical study design provides for injecting these cells into the affected limb to reduce the potential for limb amputation. It also will offer data with respect to the safety of this procedure.

This U.S. clinical study is being led by Principal Investigator Mark D. Iafrati, M.D., Chief of Vascular Surgery at Tufts Medical Center, Boston. In addition, the CLI Study is also enrolling subjects at: Roper St. Francis Healthcare, Charleston, S.C.; Methodist Hospital, Houston; University of South Florida Health, Tampa, Fla.; Maimonides Medical Center, Brooklyn, N.Y.; and Vascular Associates of Albany, Albany, N.Y.

Published studies in this area have used complicated methods to process and concentrate adult stem cells from a patient's bone marrow. The BMAC System is the first to offer clinicians a simple, easy point-of-care method to prepare a concentration of stem and precursor cells from a small aspirate of autologous bone marrow in just 15 minutes.

Harvest Technologies is a privately held company based in Plymouth, Mass.

Read the full story at http://www.prweb.com/releases/harvest_technologies/bmac_system/prweb1539624.htm


'/>"/>
Source: PRWeb
Copyright©2008 Vocus, Inc.
All rights reserved  

Related medicine news :

1. 2008 Idaho Potato Harvest Forecast: Plentiful, High-Quality Spuds
2. MAQUET Cardiovascular Responds to Terumo Complaint About VASOVIEW Endoscopic Vessel Harvesting Systems
3. Americas Second Harvest Provides Emergency Food and Water to Tropic Storm Fay Evacuees
4. Fresh Harvest Products, Inc. Announces New Brand Initiative
5. New Technique Harvests Stem Cells at Earlier Stage
6. American Red Cross Honors Americas Second Harvest at Heritage of Service Dinner
7. CalbaTech Announces $999,926 Reduction in Debt; First Adult Stem Cell Harvesting Scheduled
8. Quaker Introduces Simple Harvest(TM) All Natural Multigrain Chewy Granola Bars That Taste Simply Delicious
9. Osteotech Signs Agreement To Distribute Harvest Technologies BMAC(TM) System
10. StemCor Systems Receives FDA Clearance for Bone Marrow Harvesting System
11. Global Med Technologies(R), Inc. Implements Transfusion Management System in Large Private Physician Owned Laboratory
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
 Harvest Technologies Announces Patient Education Website, www.CLIclinicalstudy.com :  Supports first randomized, placebo-controlled clinical trial in the U.S. using autologous adult stem cells to treat patients with end-stage Critical Limb Ischemia 
(Date:2/22/2017)... , ... February 22, 2017 , ... Gevir, a New ... antler velvet, announced its products are coming soon to Amazon.com, the world’s largest online ... Thomson as a means to develop an effective natural treatment for Shelley’s Multiple Sclerosis, ...
(Date:2/22/2017)... CA (PRWEB) , ... February 22, 2017 , ... ... treatment to the thousands of individuals who have recently fallen victim to America’s opioid ... in Orange County, California, where they are free from the shame, stigma, and ...
(Date:2/22/2017)... ... February 22, 2017 , ... The National Academy of Certified ... the April 2017 testing period. NACCM, a nonprofit organization, has provided the premier ... exam is periodically re-calibrated to ensure that newly certified professionals are prepared to ...
(Date:2/22/2017)... ... February 22, 2017 , ... Giving patients with diabetes customized ... room, fewer hospital admissions, and better blood pressure and glycemic control, a ... study can be found here . , The study comes as health ...
(Date:2/22/2017)... ... February 22, 2017 , ... In a 2012 survey, over ... not filling a prescription because they could not afford to pay for it. ... were 30-60%*. At the same time, hospitals, pharmacies, manufacturers and nursing ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... , Feb. 23, 2017 ... clinical-stage oncology drug development company, announces that it ... Drug Administration (FDA) authorizing the initiation a Phase ... treatment for pancreatic cancer. MVT-1075 ( 177 Lu-CHX-A?-DTPA-HuMab5B1) ... (RIT). MabVax plans to initiate the phase I ...
(Date:2/23/2017)... VANCOUVER, British Columbia , Feb. 23, ... ) today announced its year end 2016 financial results.  ... January 2017, OncoGenex, and Achieve Life Science, Inc., a privately ... into a definitive merger agreement under which OncoGenex will ... the proposed merger, Achieve,s stockholders are expected to own ...
(Date:2/23/2017)... 2017 This report analyzes analyzes the worldwide markets for ... comprehensive analytics for the US, Canada , ... Asia-Pacific , Latin America ... provided for the period 2015 through 2022. Also, a six-year ... analytics are derived from primary and secondary research. Company profiles ...
Breaking Medicine Technology: